24 unknown. 24 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 24 | Unknown 24 |
| Phase 1 | 1 | Unknown 1 |
| Phase 3 | 1 | Unknown 1 |
Follow Diffuse Large B-Cell Lymphoma: new trials by email Literature Review of Diffuse Large B-Cell Lymphoma trials Research Report on Diffuse Large B-Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Mitoxantrone Hydrochloride Liposome Injection in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Mitoxantrone Hydrochloride Liposome Injection - Diffuse Large B-Cell Lymphoma | Phase 2 | Unknown | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 104 | 2023-07-10 | 2024-02-08 |
| Orelabrutinib Combined With R-CDOP for DLBCL Patients With High-risk of CNS Relapse Defined by CNS-IPI Orelabrutinib combined with R-CDOP regimen - Diffuse Large B-cell Lymphoma | Phase 2 | Unknown | Second Affiliated Hospital, Zhejiang University, School of Medicine | 62 | 2023-03-30 | 2024-03-04 |
| Mitoxantrone Hydrochloride Liposome Combined With Rituximab and Lenalidomide (M+R2) in Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma Mitoxantrone Hydrochloride Liposome, Rituximab, Lenalidomide - Diffuse Large B-cell Lymphoma | Phase 2 | Unknown | Jianfeng Zhou | 55 | 2022-10-10 | 2022-10-12 |
| Chidamide, Azacitidine Combined With GM Regimen for Relapsed and Refractory DLBCL Patients Chidamide, Azacitidine, obinutuzumab - Diffuse Large B-Cell Lymphoma | Phase 2 | Unknown | The First Affiliated Hospital of Soochow University | 23 | 2022-09-30 | 2023-04-21 |
| Orelabrutinib With R-CHOP-like Regimen for Patients With Newly Diagnosed Untreated Non-GCB DLBCL Orelabrutinib, Rituximab, CHOP-like Regimen - Diffuse Large B-Cell Lymphoma | Phase 2 | Unknown | The First Affiliated Hospital of Soochow University | 46 | 2022-07-27 | 2023-02-03 |
| A Study of Anlotinib Hydrochloride Capsules in Subjects With Diffuse Large B-Cell Lymphoma Anlotinib Hydrochloride Capsules - Diffuse Large B-cell Lymphoma | Phase 2 | Unknown | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 30 | 2021-04-01 | 2021-04-01 |
| A Study of TQ-B3525 in Subjects With Relapse/Refractory Diffuse Large B-cell Lymphoma (DLBCL) TQ-B3525 tablets - Diffuse Large B-cell Lymphoma | Phase 2 | Unknown | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 93 | 2021-01-20 | 2021-08-18 |
| Toripalimab Combine With Rituximab for Treatment of Relapsed Refractory CD20 Positive Diffuse Large B-cell Lymphoma Toripalimab combine with Rituximab - Diffuse Large B-cell Lymphoma, Rituximab | Phase 2 | Unknown | Chinese Academy of Medical Sciences | 20 | 2020-06-15 | 2020-06-16 |
| Sintilimab Plus R-CHOP as the First-line Treatment in Patients With Diffuse Large B-Cell Lymphoma. Sintilimab-R-CHOP - Diffuse Large B-Cell Lymphoma, Sintilimab | Phase 2 | Unknown | Chinese Academy of Medical Sciences | 30 | 2019-12-01 | 2019-12-11 |
| BUCY+VP-16 vs BUCY Conditioning Regimen for DLBCL Undergoing Auto-HSCT Busulfan (BU), Cyclophosphamide (CY), Etoposide (VP-16) - Autologous Hematopoietic Stem Cell Transplantation, Diffuse Large B-cell Lymphoma | Phase 2 / Phase 3 | Unknown | Nanfang Hospital, Southern Medical University | 122 | 2017-07-05 | 2017-10-12 |
| Abbreviated 3 Cycles of Rituximab Plus CHOP(Cyclophosphamide, Adriamycin, Vincristine, and Prednisolone) Immunochemotherapy in Patients With Completely Excised LocalizedGastrointestinal CD(Cluster of Differentiation Antigen)20(+) Diffuse Large B-cell Lymphoma Abb-R-CHOP - Diffuse Large B-cell Lymphoma | Phase 2 | Unknown | Asan Medical Center | 36 | 2016-12-07 | 2018-01-16 |
| Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma Chidamide, Vinorelbine, Liposomal Doxorubicin or mitoxantrone - Diffuse Large B-cell Lymphoma | Phase 2 | Unknown | Henan Cancer Hospital | 20 | 2016-05-01 | 2020-04-01 |
| Chidamide Plus R-CHOP in Elderly DLBCL Rituximab, Cyclophosphamide, Doxorubicin - Diffuse Large B-cell Lymphoma | Phase 2 | Unknown | Ruijin Hospital | 49 | 2016-04-01 | 2017-11-14 |
| Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma Cyclophosphamide, Cytarabine, Doxorubicin Hydrochloride - Adult Burkitt Lymphoma, B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma | Phase 1 / Phase 2 | Unknown | Northwestern University | 38 | 2015-10-28 | 2022-02-21 |
| A Study of Bortezomib Plus GDP in the Treatment of Refractory and Relapsed Non-GCB DLBCL Bortezomib, Gemcitabine, Dexamethasone - Diffuse Large B-cell Lymphoma | Phase 2 | Unknown | Ruijin Hospital | 30 | 2015-05-01 | 2017-11-14 |
| Phase II Study Comparing LR-GEM to R-GEM-P in Second-line Treatment of Diffuse Large B-cell Lymphoma (LEGEND) Gemcitabine, Methylprednisolone, Rituximab - Diffuse Large B-Cell Lymphoma | Phase 2 | Unknown | Royal Marsden NHS Foundation Trust | 92 | 2013-09-01 | 2019-09-19 |
| Interim PET/CT Guided Cycle Numbers of R-CHOP in DLBCL R-CHOP - Diffuse Large B-cell Lymphoma | Phase 2 | Unknown | Fudan University | 196 | 2013-02-01 | 2013-03-05 |
| STORM: Temsirolimus, Rituximab and DHAP for Relapsed and Refractory Diffuse Large B-cell Lymphoma Rituximab, Temsirolimus, DHAP, intravenous - Diffuse Large B-Cell Lymphoma | Phase 2 | Unknown | Mathias Witzens-Harig | 88 | 2012-09-01 | 2016-10-27 |
| Trial of R-GemOx Regimen in Previously Untreated Elderly Patients With DLBCL. R-GemOx - Diffuse Large B-cell Lymphoma | Phase 2 | Unknown | The First Affiliated Hospital with Nanjing Medical University | 60 | 2012-08-01 | 2019-02-15 |
| Phase II Prospective Trial of Addition of Rituximab to Reduced Dose CHOP Chemotherapy in DLBC L Patients Aged 65 Years and Over Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone - Diffuse Large B-cell Lymphoma | Phase 2 | Unknown | Pusan National University Hospital | 57 | 2012-08-01 | 2016-06-09 |
Showing 20 of 24. Sign in to see all of them.
Lymphoma, Large B-Cell, Diffuse (24) · Recurrence (2) · Burkitt Lymphoma (1) · Lymphoma, B-Cell (1) · Lymphoma, Non-Hodgkin (1) · Plasmablastic Lymphoma (1)
Hemic and Lymphatic Diseases (24) · Immune System Diseases (24) · Immunoproliferative Disorders (24) · Lymphatic Diseases (24) · Lymphoma (24) · Lymphoproliferative Disorders (24) · Neoplasms (24) · Neoplasms by Histologic Type (24) · Lymphoma, B-Cell (23) · Lymphoma, Non-Hodgkin (23) · Disease Attributes (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · DNA Virus Infections (1) · Epstein-Barr Virus Infections (1)
Rituximab (13) · Cyclophosphamide (5) · Doxorubicin (4) · Prednisone (4) · Vincristine (4) · Gemcitabine (3) · N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide (3) · Cisplatin (2) · Cytarabine (2) · Dexamethasone (2) · Etoposide (2) · Lenalidomide (2) · R-CHOP protocol (2) · Azacitidine (1) · Bortezomib (1)
Asan Medical Center (2) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (2) · Chinese Academy of Medical Sciences (2) · Fondazione Italiana Linfomi - ETS (2) · Fudan University (2) · Ruijin Hospital (2) · The First Affiliated Hospital of Soochow University (2) · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (1) · Henan Cancer Hospital (1) · Jianfeng Zhou (1) · Mathias Witzens-Harig (1) · Nanfang Hospital, Southern Medical University (1) · Northwestern University (1) · Pusan National University Hospital (1) · Royal Marsden NHS Foundation Trust (1)
China (14) · Italy (2) · Germany (1) · South Korea (1) · United Kingdom (1) · United States (1)
Michele Spina, MD (2) · Ye Guo, MD (2) · Barbara Pro, MD (1) · Cheolwon Suh, MD, PhD (1) · David Cunningham, MD FRCP (1) · Ho-Jin Ho-Jin (1) · Mathias Witzens-Harig, MD (1) · Qifa Liu (1) · Weili Zhao, Prof (1) · Wenbin Qian (1) · Yanyan Liu, M.D. Ph.D (1) · Yuankai Shi, M.D (1)
PMID 18213528, PMID 18824292, PMID 1950172, PMID 20686505, PMID 21390126, PMID 21796119, PMID 22080169, PMID 22339555, PMID 22362161, PMID 23799873, PMID 24721323, PMID 25652253, PMID 25712263, PMID 29748444, PMID 29752199, PMID 32989495, PMID 33097085, PMID 35418080, PMID 38237077
2009 (1), P30CA060553 (1)